FABOLUS-FASTER Phase IV trial of Aggrastat in acute coronary syndrome published in Circulation.- Medicure
Related news and insights
Amgen announced positive data from the HUYGENS Phase III study showing that Repatha(evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features of plaque stability in patients with coronary artery disease (CAD). These data are being presented during an oral presentation at ESC Congress 2021, organized by the European Society of Cardiology, Aug. 27-30.
Medicure announced that results from the investigator sponsored FABOLUS-FASTER Phase IV clinical trial, using Aggrastat (tirofiban) in acute coronary syndrome, have been published in Circulation, a peer-reviewed journal of the American Heart Association.
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.